Syngene International Limited (BOM:539268)
India
· Delayed Price · Currency is INR 649.50
+6.85 (1.07%)
At close: Aug 12, 2025
Syngene International Revenue
Syngene International had revenue of 8.75B INR in the quarter ending June 30, 2025, with 10.74% growth. This brings the company's revenue in the last twelve months to 37.27B, up 7.41% year-over-year. In the fiscal year ending March 31, 2025, Syngene International had annual revenue of 36.42B with 4.41% growth.
Revenue (ttm)
37.27B
Revenue Growth
+7.41%
P/S Ratio
7.04
Revenue / Employee
5.71M
Employees
6,533
Market Cap
262.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
| Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
| Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
| Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
| Mar 31, 2021 | 21.84B | 1.72B | 8.57% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |
Syngene International News
- 19 days ago - Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains - Business Upturn
- 21 days ago - Syngene Q1 profit up 59% to Rs 87 crore - The Times of India
- 21 days ago - Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY - Business Upturn
- 2 months ago - Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification - Business Upturn
- 3 months ago - Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY? - Business Upturn
- 3 months ago - Syngene International shares hit lower circuit crashing to 10% today after Q4 results - Business Upturn
- 6 months ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 6 months ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn